| Affix Patient Label here or record: | | | | | | | | | | |
|-------------------------------------|----|----|-----|---|----|---|-----|----|------|---|
| Name: | | | | | | | | | | |
| NHS No: | | | | | | | | | | |
| Hosp No: | | | | | | | | | |] |
| D.O.B: D | D/ | MI | л/Г | Ý | ΥY | M | ale | Fe | male | |

| | NHS |
|-------|-------------------------|
| | estershire Hospitals |
| Acute | NHS Trust |

ALX

WRH KTC

Emergency Department / Orthopaedics VTE Risk Assessment for Patients in Lower Limb PoP / Immobilisation

Complete this form for any patient over the age of 16yrs who is being placed in lower limb immobilisation or NWB.

| VTE RISK Factors for VTE – t | Obesity (BMI > 30) Use of HRT or tamoxifen Active cancer or cancer treatment Varicose veins with evidence of phlebitis Known Thrombophilia Active smoker | | | | |
|--------------------------------------|---|--|---|--|--|
| Age > 60 years | Previous DVT or PE 1st degree relative with Hx of VTE | | NO 🗌 risk | | |
| Obesity (BMI > 30) | Use of HRT or tamoxifen | | factors | | |
| Active cancer or cancer treatment | Varicose veins with evidence of phlebitis | | identified. | | |
| Known Thrombophilia | Active smoker | | Routine care only, form | | |
| Pregnancy or \leq 6/52 post-partum | Serious medical co-morbidity | | is now completed – ensure it is scanned into | | |
| Recent in-patient (<6/52) | Prolonged (>48hr) new immobility pre or post injury | | the patient's notes | | |

| Please tick any Contra-indications | to Thromboprophylaxis | |
|---|--|---|
| Active bleeding from any site | Thrombocytopenia (Platelet count <75x109) | If any boxes have been ticked then |
| Untreated hereditary bleeding disorders | Recent spinal or epidural surgery or LP | the patient is |
| Risks outweigh benefits i.e falls risk | Concurrent acute CVE or intra cranial Bleed last 6 weeks | NOT suitable for thromboprophylaxis |
| Already on anticoagulation or DOAC | Upper GI bleed within weeks or known varices / peptic ulcer | (enoxaparin or rivaroxaban) despite |
| \leq 6/52 of Major Trauma / Eye / CNS surgery | Severe hypertension >180/110mmHg or uncontrolled hypertension | having a risk of VTE – these cases should be |
| Known vascular aneurysm | Acquired bleeding tendencies or Liver failure (INR >1.3) | discussed with Senior Doctor |

If no boxes have been ticked then your patient is eligible for thromboprophylaxis Rivaroxaban may be used unless any of the following contraindications apply

| Hypersensitivity / reaction to DOAC | Pregnancy, Breast feeding, | , Post-partum (6/52) | If any boxes have been ticked then use |
|--|-------------------------------|-----------------------|--|
| Malignant neoplasm at risk of bleeding | Renal disease CrCl<30 mL | /min or Cr>400 umol/L | enoxaparin if CrCl |
| Anti-phospholipid syndrome | Drug interactions (see box1 - | – overleaf) | >15ml/min. |

Management

| Management | | | |
|----------------------------------|---|--|-----------------------------|
| Notes on the reverse of this fo | rm have been read | | |
| Explain the management and | symptoms of DVT/PE and gain verbal c | onsent for treatment | |
| Only request FBC, U&Es, and I | FTS if known or suspicion of renal dise | ase or bleeding disorder or anaemia | |
| Give the patient the information | on leaflet for rivaroxaban / enoxaparin | PLUS the DVT / PE prevention leaflet | |
| Prescribe the TTO Thrombopro | phylaxis (rivaroxaban / enoxaparin) [an | outpatient prescription or FP10] (see bo | ox 3 for dosing) |
| Ensure Trauma Clinic or other | specified follow-up, for example if out | of area | |
| Use GP Free Text in Patient Firs | st or Clinic Letter to inform GP of Thror | nboprophylaxis prescription | |
| Prescribed Thrombopr | | xaban (adults) 🛛 🗌 None (d parin (Inhixa) | ocument reasoning in notes) |
| | Requesting healt | h professional | |
| Name: | Designation: | Registration No: | Date: |





| Affix Patient Label here or record: | | | | | | | | | | |
|-------------------------------------|----|----|-----|---|----|---|-----|----|------|--|
| Name: | | | | | | | | | | |
| NHS No: | | | | | | | | | | |
| Hosp No: | | | | | | | | | | |
| D.O.B: D | D/ | MI | л/Г | Ý | ΥY | M | ale | Fe | male | |

Notes

- ALL patients with any of the following risk factors:
 - -Rigid immobilisation (above or below knee) e.g. Plaster of Paris -Non-weight bearing status
 - -Acute severe injury (dislocation, fracture or complete tendon rupture)

MUST be risk stratified and commenced on prophylactic anticoagulation if appropriate.

- If the patient is on Oral Contraceptive Pills containing Oestrogen, the tablets must be stopped for the entire duration that the POP/ cast is on and alternate methods of contraception must be used but no thromboprophylaxis is required.
- If your patient is on warfarin, you MUST check the INR and ensure that the INR is > 2, this may or may not require a change in warfarin dose. Do not prescribe additional thromboprophylaxis if the patient is already taking therapeutic anticoagulation.
- As an alternative to enoxaparin if it cannot be used due to religious reasons, use fondaparinux 2.5mg OD (unlicensed in children under the age of 17)
- Once completed this form must be scanned into the patient notes whether or not the patient receives prophylaxis.

Box 1. Rivaroxaban Drug interactions

- Ketoconazole, itraconazole, voriconazole, posaconazole
- HIV protease inhibitors
- Cobicistat
- Dronadarone
- CYP3A4 inducers (including rifampicin, phenytoin, carbamazepine, phenobarbital or St Johns Wort)

Box 2. Rivaroxaban dosing in adults (age \geq 18 years) with creatinine clearance >30ml/minute

• 10mg once daily

Box 3. Enoxaparin dosing

- Use 40mg daily in patients with CrCl >30ml/minute
- Use 20mg daily in patients with CrCl 15-29ml/minute or weighing less than 50kg
- Consider larger doses e.g. 40mg BD in patients weighing >100kg
- Give the patient the information leaflet for enoxaparin and how to inject
- Advise the patient how to inject the enoxaparin daily and show them
- Prescribe the TTO enoxaparin on an outpatient prescription or FP10
- Give patients a TTO Sharps Bin and information on disposal.
- Enoxaparin is not currently licensed for use in under 18 years of age. The prescriber should follow the relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented.



